China Economic Net, Beijing, June 23 hearing Junshi Bio (688180.SH) shares fell today to close at 74.92 yuan, or 3.02%.In the previous three trading days, the declines were 5.45%, 0.90% and 3.01% respectively.
On May 12, Junshi Bio’s stock price reached its highest point this year at 131.42 yuan during the session.
On the same day, Zhang Jinyang and Hu Ruobi, researchers of Guosheng Securities Co., Ltd., released the research report "Jushi Bio-U(688180) Company Comments: VV116 has been listed in Uzbekistan and completed the Phase 3 clinical trial of P drug head-to-head", saying that VV116 will not be considered for the time being. It is estimated that the company's revenue from 2022 to 2024 will be 2.274 billion yuan, 3.687 billion yuan, and 4.893 billion yuan, respectively, with year-on-year growth rates of -43.5%, 62.1%, and 32.7%, respectively. The net profit attributable to the parent is -1.037 billion yuan, -811 million yuan and -231 million yuan, corresponding to EPS of -1.14, -0.89, and -0.25 yuan respectively.Considering the current domestic anti-epidemic situation and Omicron's ability to spread, the approval of VV116 will bring greater revenue flexibility to the company, and we look forward to VV116's data readout.Optimistic about the company's development, maintain a "buy" rating.
